Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age
the STRIDE trial.
Joakim Nordanstig, Ecenur Guder Arslan, Andrei-Mircea Catarig et al. - European heart journal
This EHJ article presented STRIDE trial subanalyses of semaglutide in patients with peripheral artery disease and diabetes stratified by baseline disease severity and age, informing the use of GLP-1 agonists in the PAD population.
